TenNor Therapeutics' Phase III trial of rifasutenizol for H. pylori infection successfully met primary endpoints, surpassing current treatment standards. The antibiotic showed high efficacy, safety, and tolerability, offering a promising solution amid rising antimicrobial resistance concerns.